— Know what they know.
Not Investment Advice

HAE NYSE

Haemonetics Corporation
1W: +8.4% 1M: +1.3% 3M: +1.2% YTD: -22.6% 1Y: -10.2% 3Y: -30.6% 5Y: +10.6%
$65.49
+3.55 (+5.73%)
 
Weekly Expected Move ±6.8%
$49 $52 $56 $60 $64
NYSE · Healthcare · Medical - Instruments & Supplies · Alpha Radar Buy · Power 64 · $3.0B mcap · 45M float · 1.75% daily turnover · Short 65% of daily vol

Cash Flow Trends

Operating Cash Flow
$293M +61.4% ▲
5Y CAGR: +21.9%
Capital Expenditures
$33M +16.5% ▲
5Y CAGR: -2.4%
Free Cash Flow
$260M +82.8% ▲
5Y CAGR: +29.4%
Dividends Paid
$0 +0.0% ▲
Buybacks
$175M +22.2% ▲
Net Change in Cash
-$61M -147.9% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025FY2026
— Operating Activities —
Net Income$43M$115M$118M$168M$97M
Depreciation & Amort.$98M$93M$97M$116M$156M
Stock-Based Comp.$24M$26M$0$30M$0
Change in Working Capital-$15M$26M-$75M-$102M-$24M
Other Non-Cash Items$17M$8M$53M-$24M$90M
Operating Cash Flow$172M$273M$182M$182M$293M
— Investing Activities —
Capital Expenditures-$97M-$110M-$66M-$39M-$93M
Acquisitions (Net)$8M-$2M-$241M-$108M$1M
Investment Purchases$0-$33M-$16M$0$0
Investment Sales$0$0$0$0$0
Other Investing$2M$2M$0-$15M-$88M
Investing Cash Flow-$86M-$144M-$322M-$162M-$180M
— Financing Activities —
Net Debt Issuance-$18M-$10M$38M$447M-$6M
Stock Repurchased$0-$75M$0-$225M-$175M
Dividends Paid$0$0$0$0$0
Other Financing$2M-$16M-$7M-$113M-$5M
Financing Cash Flow-$16M-$100M$38M$109M-$178M
Net Change in Cash$67M$25M-$106M$128M-$61M
Cash End of Period$259M$284M$179M$307M$245M
Free Cash Flow$76M$163M$115M$142M$260M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms